



Powered by the Sharekhan 3R Research Philosophy

### 3R MATRIX

	+	=	-
Right Sector (RS)	✓	■	■
Right Quality (RQ)	✓	■	■
Right Valuation (RV)	■	✓	■

+ Positive = Neutral - Negative

### What has changed in 3R MATRIX

	Old		New
RS	■	↔	■
RQ	■	↔	■
RV	■	↔	■

### ESG Disclosure Score **NEW**

**ESG RISK RATING** 30.57  
Updated Apr 08, 2022

**High Risk**

NEGL	LOW	MED	HIGH	SEVERE
0-10	10-20	20-30	30-40	40+

Source: Morningstar


### Company details

Market cap:	Rs. 21,198 cr
52-week high/low:	Rs. 2,290 / 1,675
NSE volume: (No of shares)	0.5 lakh
BSE code:	524200
NSE code:	VINATIORGA
Free float: (No of shares)	2.7 cr

### Shareholding (%)

Promoters	74
FII	8
DII	5
Others	14

### Price chart



### Price performance

(%)	1m	3m	6m	12m
Absolute	1.1	9.6	5.2	13.9
Relative to Sensex	6.1	15.6	14.1	5.7

Sharekhan Research, Bloomberg

## Vinati Organics Ltd

### Stellar Q4, solid growth outlook

Speciality Chemicals

Sharekhan code: **VINATIORGA**

Reco/View: **Buy**



CMP: **Rs. 2,062**

Price Target: **Rs. 2,450**



Upgrade



Maintain



Downgrade

### Summary

- Vinati Organics ended FY22 on strong note with a massive beat of 24%/35%/21% in Q4FY22 revenue/operating profit/PAT at Rs. 486 crore/Rs. 139 crore/Rs. 101 crore, up 32%/50%/22% q-o-q. We believe that robust growth was led by strong volume growth across products, ATBS margin recovery and ramp-up of Butyl Phenol.
- Improved growth outlook across products - ATBS to benefit given elevated oil prices, IBB to witness robust growth on low base of FY22 and sustained revenue ramp-up for butyl phenol. Margins to recover to 30-31% given operating leverage and a favourable base (FY22 OPM contracted by 1,070 bps y-o-y to 27%).
- The management had earlier guided to almost double its revenues to Rs. 3,000 crore by FY25 and sustainable margin of ~30% driven by optimum expansion of existing products (like ATBS) and ramp-up of new products (Butyl Phenol, anti-oxidants and five specialty intermediates).
- We maintain a Buy rating on Vinati Organics with a revised PT of Rs. 2,450 given our expectations of strong 33% PAT CAGR over FY22-24E, dominant market share in ATBS/IBB, entry into newer products and improvement in RoE/RoCE to 25%/32%.

Vinati Organics Limited's (Vinati Organics) reported robust consolidated revenue growth of 74%/32% y-o-y/q-o-q to Rs. 486 crore, a sharp beat of 24% versus our estimate of Rs. 392 crore. Moreover, OPM at 28.6% (up 341 bps q-o-q) beat our estimate by 235 bps led by benefit of operating leverage driven by sharp rise in revenues versus a 3% q-o-q decline in operating cost (as a percentage of revenues declined by 628 bps q-o-q to 17.5%). Resultantly, operating profit was up by 50% q-o-q to Rs. 139 crore, which was 35% above our estimate of Rs. 103 crore. We believe that a strong revenue/earnings growth was primarily driven by robust volume recovery across products segments (ATBS, IBB & Butyl Phenols), recovery in ATBS led by higher demand from oil & gas given elevated oil price and better prices and ramp-up of revenues from butyl phenol. PAT at Rs. 101 crore (up 42.7% y-o-y; up 21.5% q-o-q) was also 21% above our estimate led by robust revenue/margin performance partially offset by higher tax rate of 28.8%.

### Key positives

- Sharply higher-than-expected revenue growth of 74%/32% y-o-y/q-o-q.
- Beat in OPM by 235 bps to 28.6%, up 341 bps q-o-q led by benefit of operating leverage.

### Key negatives

- Lower-than-expected gross margin of 46.1%, down 287 bps q-o-q and miss of 93 bps versus our estimate of 47%.

**Revision in estimates** – We have fine-tuned our FY23 earnings estimate and increase FY24 earnings estimate to factor higher growth in ATBS and faster ramp-up of revenues from new products.

### Our Call

**Valuation** – We maintain **Buy** on Vinati Organics with a revised PT of **Rs. 2,450**: Vinati Organics' dominant global market share in ATBS/IBB segments, niche product portfolio and a massive export opportunity in the specialty chemical sector would drive sustained long-term high double-digit earnings growth. Likely higher ATBS margin and ramp-up of butyl phenol would drive strong 33% PAT CAGR over FY2022-FY2024E along with solid RoE of 24.7%. Potential incremental earnings contribution from integration of Veeral Additives (VAPL) would further aid earnings growth. Hence, we maintain Buy on Vinati Organics with a revised PT of Rs. 2,450 (reflects upward revision in FY24 earnings estimate). Stock is trading at 43.9x its FY2023E EPS and 34.5x its FY2024E EPS.

### Key Risks

- Lower demand due to economic slowdown and delay in the completion of expansion projects might affect revenue growth.
- Higher raw-material prices and delay in the ability to pass on price hikes adequately and adverse forex fluctuations might affect margins.

### Valuation (Consolidated)

Particulars	Rs cr			
	FY21	FY22	FY23E	FY24E
Revenue	954	1,616	2,101	2,629
OPM (%)	36.9	26.9	30.4	30.9
Adjusted PAT	269	347	482	614
y-o-y growth (%)	(19.3)	28.7	39.2	27.3
Adjusted EPS (Rs.)	26.2	33.7	46.9	59.8
P/E (x)	78.7	61.2	43.9	34.5
P/BV (x)	13.7	11.6	9.5	7.7
EV/EBITDA (x)	59.6	48.9	32.5	25.1
RoCE (%)	22.5	25.2	30.2	31.6
RoE (%)	19.1	20.6	23.8	24.7

Source: Company; Sharekhan estimates

## Robust Q4; revenue/PAT beat estimate by 24%/21%


Robust Q4FY22 consolidated revenue growth of 74%/32% y-o-y/q-o-q to Rs. 486 crore, sharp beat of 24% versus our estimate of Rs. 392 crore. Moreover, OPM at 28.6% (up 341 bps q-o-q) beat our estimate by 235 bps led by benefit of operating leverage driven by sharp rise in revenues versus 3% q-o-q decline in operating cost (as percentage of revenues declined by 628 bps q-o-q to 17.5%). Resultantly, operating profit was up by 50% q-o-q to Rs. 139 crore, which was 35% above our estimate of Rs. 103 crore. We believe that strong revenue/earnings growth was primarily driven by robust volume recovery across products segments (ATBS, IBB & Butyl Phenol), a recovery in ATBS led by higher demand from oil & gas given elevated oil price and better prices and ramp-up of revenues from butyl phenol. PAT at Rs. 101 crore (up 42.7% y-o-y; up 21.5% q-o-q) was also 21% above our estimate led by robust revenue/margin performance partially offset by higher tax rate of 28.8%.

### Results (Consolidated)

Particulars	Rs cr				
	Q4FY22	Q4FY21	Y-o-Y %	Q3FY22	Q-o-Q %
<b>Revenue</b>	<b>486.1</b>	<b>279.8</b>	<b>73.7</b>	<b>369.0</b>	<b>31.7</b>
Total expenditure	347.3	180.6	92.3	276.2	25.8
<b>Operating profit</b>	<b>138.8</b>	<b>99.1</b>	<b>40.0</b>	<b>92.8</b>	<b>49.6</b>
Other Income	15.1	6.6	130.7	14.6	3.6
Depreciation	11.7	48.8	(76.1)	11.5	1.5
Finance Cost	0.2	10.7	(97.8)	0.0	NA
PBT	142.0	94.8	49.7	95.8	48.2
Tax	40.9	24.0	70.5	12.6	224.0
<b>PAT</b>	<b>101.1</b>	<b>70.8</b>	<b>42.7</b>	<b>83.2</b>	<b>21.5</b>
EPS (Rs)	9.8	6.9	42.7	8.1	21.5
<b>Margin (%)</b>			<b>bps</b>		<b>bps</b>
OPM	28.6	35.4	(688)	25.1	341
NPM	20.8	25.3	(453)	22.6	(176)
Tax rate	28.8	25.3	351	13.2	1,563


Source: Company; Sharekhan Research

### Robust Q4FY22 revenues




Source: Company; Sharekhan Research

**Gross margin remain muted**




Source: Company; Sharekhan Research

**Sharp decline in opex as percentage of revenue in Q4FY22**



Source: Company; Sharekhan Research

**EBITDA margin improves q-o-q on operating leverage**



Source: Company; Sharekhan Research

## Outlook and Valuation

### ■ Sector view – Structural growth drivers to propel sustained growth for the specialty chemicals sector in the medium to long term

We remain bullish on the medium to long-term growth prospects of specialty chemicals sector, given a massive revenue opportunity from the perspective of import substitution (India's total specialty chemical imports are estimated at \$56 billion), potential increase in exports given China Plus One strategy by global customers, and favourable government policies (such as tax incentive and production-linked incentive scheme). In our view, conducive government policies, product innovation, a massive export opportunity, and low input prices would help the sector witness a sustained high double-digit earnings growth trajectory in the next 2-3 years.


### ■ Company outlook – Niche business with significant market share, improvement in ATBS demand bodes well for earnings recovery:

Vinati Organics operates in niche segments and has an exceptional product basket that holds a significant market share globally. Hence, the company is able to generate significantly higher margins. This coupled with a debt-free balance sheet helps Vinati Organics generate superior return ratios. A potential recovery in ATBS margins and demand and ramp-up of butyl phenol would lead to a 33% PAT CAGR over FY2022-FY2024E.

### ■ Valuation – We maintain a Buy on Vinati Organics with a revised PT of Rs. 2,450

Vinati Organics' dominant global market share in ATBS/IBB segments, niche product portfolio and a massive export opportunity in the specialty chemical sector would drive sustained long-term high double-digit earnings growth. Likely higher ATBS margin and ramp-up of butyl phenol would drive strong 33% PAT CAGR over FY2022-FY2024E along with solid RoE of 24.7%. Potential incremental earnings contribution from integration of Veeral Additives (VAPL) would further aid earnings growth. Hence, we maintain Buy on Vinati Organics with a revised PT of Rs. 2,450 (reflects upward revision in FY24 earnings estimate). Stock is trading at 43.9x its FY2023E EPS and 34.5x its FY2024E EPS.

#### One-year forward P/E (x) band



Source: Sharekhan Research

xxxx

## About company

Incorporated in 1989, Vinati Organics is one of India's leading manufacturers and exporters of specialty organic intermediaries, monomers, and polymers. Vinati Organics is the world's largest manufacturer and seller of Isobutyl Benzene (IBB) and 2-Acrylamido 2-Methylpropane Sulfonic Acid (ATBS) having a significant market share in both the product categories. The company currently has a capacity of 25,000 TPA for IBB and 26,000 TPA for ATBS. Vinati Organics is an export-oriented company, as 70-75% of its overall revenue are derived from export markets.

## Investment theme

Vinati Organics operates in niche segments and have an exceptional product basket with a significant market share in its products globally. Hence, the company is able to generate significantly higher margin profile. This coupled with a lean balance sheet (debt-free company) helps Vinati Organics to generate superior return ratios. Vinati Organics is expected to see increased volumes in ATBS (2-Acrylamido 2 Methylpropane Sulfonic Acid) due to capacity expansion, while IB (Isobutylene) volumes are expected to rise due to enhancement of capacity utilisation and a gradual ramp-up in utilisation levels for butyl phenol.

## Key Risks

- ◆ Lower demand due to an economic slowdown and delay in completion of expansion projects might impact revenue growth.
- ◆ Adverse raw-material prices and delay in the ability to pass on price hikes adequately and forex fluctuations might affect margins

## Additional Data

### Key management personnel

Vinod Saraf	Chairman
Vinati Saraf Mutreja	Managing Director and CEO
Viral Saraf Mittal	Director-CSR and Corporate Strategy
Sunil Saraf	Non-Independent Director
N. K. Goyal	Chief Financial Officer
Milind A. Wagh	Company Secretary and Compliance Officer

Source: Company Website

### Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Mirae Asset Global Investments Co Ltd	3.94
2	Canara Robeco Asset Management Co Ltd	1.65
3	Invesco Asset Management India Pvt Ltd	1.29
4	Investor Education and Protection Fund	1.20
5	Capital Group Cos Inc	0.84
6	Vanguard Group Inc	0.74
7	Goldman Sachs Group Inc	0.63
8	Blackrock Inc	0.41
9	Dimensional Fund Advisors LP	0.31
10	William Blair & Co LLC	0.27

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

## Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

# Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

**Disclaimer:** This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that neither he or his relatives or Sharekhan associates has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either, SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: [compliance@sharekhan.com](mailto:compliance@sharekhan.com);

For any queries or grievances kindly email [igc@sharekhan.com](mailto:igc@sharekhan.com) or contact: [myaccount@sharekhan.com](mailto:myaccount@sharekhan.com)

**Registered Office:** Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on [www.sharekhan.com](http://www.sharekhan.com); Investment in securities market are subject to market risks, read all the related documents carefully before investing.